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ABSTRACT
Primary hyperparathyroidism (PHPT) diagnosis is challenging and is based on serum calcium (Ca) and parathyroid hormone (PTH).
Because serum Ca and phosphorous (P) are inversely related in PHPT, we investigated the diagnostic value of the serum Ca/P ratio in
the diagnosis of PHPT. We report a single-center, case-controlled, retrospective study including 97 patients with documented PHPT
and compared them with those of 96 controls (C). The main outcome measures were: serum PTH, 25-OH vitamin D, Ca, P, albumin,
and creatinine. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the serum Ca/P ratio were
calculated. The results were verified using an independent, anonymous set of data extracted from a laboratory database containing
over 900million entries. A total of 35 (36.1%) PHPT patients had normocalcemic PHPT (NCHPT). Ca and PTHwere significantly higher
in PHPT than in C (p< 0.0001). P was significantly lower in PHPT than in C (p< 0.0001). The Ca/P ratio was significantly higher in PHPT
than in C (p< 0.0001). Receiver-operating characteristic (ROC) curves analyses identified a cutoff of 2.71 (3.5 if Ca and P are expressed
in mg/dL) for Ca/P ratio with a sensitivity and specificity of 86% and 87%, respectively (p< 0.0001), confirmed by the independent,
big data approach. In conclusion, Ca/P is a valuable tool for the diagnosis of PHPT and is of superior value compared to serum Ca
alone, especially in NCPHT. Because Ca/P is simple, inexpensive, and easily accessible worldwide, this ratio is useful for PHPT
diagnosis, especially in laboratory/medical settings relying on limited resources, such as low-income countries. © 2017 The Authors.
JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.
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Introduction
Primary hyperparathyroidism (PHPT) is the third mostcommon endocrine disorder(1) and is the most common
cause of hypercalcemia in the outpatient setting.(2) PHPT should
be considered in any person with elevated serum calcium (Ca)
levels and no clear evidence of malignancy.(3) Similarly, PHPT
should be considered in case of hypophosphatemia because the
latter is present in 10% to 20% of patients with PHPT.(4)
The biochemical profile of PHPT is classically characterized by
elevated serum intact parathyroid hormone (PTH) levels coupled
with hypercalcemia and slight or mild hypophosphatemia (with
or without hypercalciuria).(1,3) Thus, the diagnosis of PHPT is
based on the combination of hypercalcemia and elevated PTH.(3)
However, not all PHPT patients exhibit this biochemical pattern.
Normohormonal PHPT (NHPHPT) and normocalcemic PHPT
(NCPHPT) are characterized by serum PTH close to the upper
limit, but still within the normal range(5,6) and by normal serum
Ca (often in the highest quartile of the normal range),(7)
respectively. Even though they are in the normal range in
NHPHPT and NCPHPT, serum Ca and phosphorous (P) levels are
very close to the highest and lowest limit of the normal range,
respectively.(5–7) To complicate the picture, clinical signs and
symptoms are not always present, as in asymptomatic PHPT.(8)
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Hence, the diagnosis of PHPT is challenging(1,3) and often
delayed(2) because of this wide spectrum of clinical and
biochemical manifestations, especially in asymptomatic and
NCPHPT patients.(8) For all these reasons, physicians cannot
completely rule out the diagnosis of PHPT even in presence of
normal PTH or normal serum calcium.(9)
Since the 1970s the diagnosis of PHPT has dramatically
increased in parallel with the introduction of measurement of
serum Ca in clinical practice, because of the development of
automatic chemistry analyzers.(2,10) Several strategies have been
explored in the past aiming to identify tools useful to easy
diagnose or screen PHPT. Among them, biochemical markers
used alone (eg, urinary Ca excretion, serum P, alkaline phospha-
tase) or in combination were tested without success.(11,12) Serum
Cawas graphically related to both serumP andPTH in an attempt
to improve the diagnostic value of these measurements, but
resulted only in a mirroring image of data.(13) The chloride to
phosphorous ratio(14) and other complex metabolic tests,(15,16)
such as the measurement of tubular reabsorption of phos-
phate(17) and the calcium tolerance test,(12) had no diagnostic
value and never entered in the diagnostic work up of PHPT.(18)
During the last decades several other biochemical parameters,
such as cyclic adenosine monophosphate renal excretion(19,20)
and other complex nomograms(21,22) or diagrams, including the
renal phosphorous threshold,(23)were testedwithout success and
none of them was introduced in routine clinical practice due to
their inaccuracy, complexity, or both.
Ca and P homeostasis are directly interrelated because serum
Ca interplays with serum P through the modulation of several
hormones; for this reason their serum concentration is
approximately inversely related.(24,25) Even in PHPT serum Ca
and P are inversely related,(13) thus the Ca to P ratio (Ca/P) might
be considered a good candidate tool for the diagnosis of PHPT.
Surprisingly, no data on Ca/P ratio are available in literature,(11)
despite the fact that they are very simple biochemical
measurements largely available in any clinical laboratory setting.
The aim of this study is to investigate the diagnostic value of
the Ca/P ratio in the diagnosis of PHPT.
Patients and Methods
Study design
A single-center, retrospective, case-control investigation, con-
sisting of two trials, was carried out. The first trial was a
retrospective analysis of patients followed in our center
subdivided in two groups: patients with a certain diagnosis of
PHPT (cases) and disease-free subjects (controls). This trial was
registered in ClinicalTrials.gov (Identifier: NCT03027349).
The second trial was an analysis of data extracted from a
database of over 900 million laboratory records interrogated to
verify the validity of the findings of the clinical trial.
Trial 1: subjects
After reviewing the record charts of all patients with PHPT who
had been diagnosed at our center from 2005 to 2015, a total of
97 patients with a documented diagnosis of PHPTwere included
in the study (Fig. 1). The outcome measurements that had to be
present in the charts for inclusionwere: age, gender, serumCa, P,
PTH, 25-OH vitamin D, and creatinine. Both patients with
NCPHPT and hypercalcemic PHPT were included (Table 1, Fig. 1).
As a control group, we retrospectively selected patients who
attended the same center in the same time period, matched by
age. Only patients with both serum PTH and Ca within the
normal range and complete data set were considered.
Exclusion criteria for both cases and controls were as follows:
age younger than18years or older than90years; severe renal and
liver diseases (ie, glomerular filtration rate [GFR] <30mL/min);
hyperparathyroidism secondary to vitamin D deficiency; active
metabolic bone disease (eg, Paget’s disease of the bone,
osteomalacia, rickets); any type of cancer; malnutrition; severe
obesity (BMI>40 kg/m2); a history of gastrointestinal malabsorp-
tion; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthy-
roidism, pseudohypoparathyroidism; familial hypocalciuric
hypercalcemia [FHH]; hypophosphatemia not due to PHPT (eg,
genetic causes); and treatment with steroids, active forms of
vitamin D (calcitriol, ergocalciferol, etc.), thiazides, phosphate
binders, lithium, cinacalcet, bisphosphonates, and denosumab.
Demographic characteristics of patients and controls are
summarized in Table 1.
Trial 2: data mining
All examinations of PTH, Ca, and P consecutively performed from
January 2010 to December 2016 in our central laboratory of the
Department of Clinical Pathology Azienda USL of Modena, Italy,
were included in a large database. The database was refined
considering only “datasets” including the simultaneous deter-
mination of Ca, P, PTH, and creatinine on the same occasion and
belonging to subjects between 18 and 90 years of age with
normal renal function, assessed by calculating GFR using the
following Modification of Diet in Renal Disease (MDRD) formula:
GFR¼ 186 (serum creatinine)1.154 (age)0.203 (1.210 if
black) (0.742 if female). Only datasets from subjects with
GFR >30mL/min were retained for final analysis. Datasets
suggesting hypoparathyroidism (PTH and/or Ca below the 5th
centile) were excluded from the analysis. The remaining datasets
were divided into: (i) PHPT (both PTH and Ca serum levels above
the 95th centile), and (ii) controls, defined by PTH and Ca serum
levels between the 5th and the 95th centile.
Laboratory analyses
Serum Ca and P were detected using Beckman Coulter AU 680
(Beckman Coulter Italy, Cassina de’ Pecchi, Milan, Italy) device by
the colorimetric photometricmethods based on Arsenazo III and
molybdate, respectively. For both sexes, the normal reference
ranges for serum Ca and P were 2.12 to 2.65mmol/L (8.5
to 10.6mg/dL) and 0.81 to 1.65mmol/L (2.5 to 5.1mg/dL),
respectively.
Serum Intact PTH was determined by a Beckman Coulter
UniCel DxI 600 Synchron Access (Beckman Coulter Italy). The
normal reference range for serum PTH is 15 to 88 ng/L, with an
intraassay variability coefficient of 5%.
Serum 25OH-Vitamin Dwasmeasured by chemiluminescence
with the LIASON XL 1,25OH-Vitamin D assay (DiaSorin, Stillwater,
MN, USA). Normal reference range is 74.9 to 249.6 nmol/L and
the intraassay and interassay variability coefficient was <10%.
In order to obtain an estimation of free Ca (corrected Ca) levels
we applied the following formula to all patients for which
serum albumin was available in the record chart: corrected
total calcium (mmol/L)¼ total serum calcium (mmol/L)þ 0.02
[40–serum albumin (g/L)].(3)
Ethics
The Institutional Review Board of Azienda USL of Modena
approved the study (Protocol n. 0032443/15).
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Statistical analysis
All data of trial 1 are shown as median and minimum to
maximum and the nonparametric Mann-Whitney U test was
used for group comparisons because variables were not
normally distributed at the Kolmogorov-Smirnov test.
Sensitivity, specificity, positive predictive value (PPV), nega-
tive predictive value (NPV), and accuracy were evaluated.(26)
The statistical analyses of the datasets of trial 2 were
performed first evaluating the variables distribution by the
Shapiro-Wilk test. The normal range for PTH, Ca, and P was
obtained calculating the 95% confidence interval (CI). The Ca/P
ratio was calculated and the difference between PHPT and
controls was evaluated by ANOVA univariate or Mann Whitney
test for normally and not-normally distributed variables,
respectively.
In both trials, the diagnostic accuracy of Ca/Pwas investigated
using receiver-operating characteristic (ROC) curves in order to
define cutoff points that better identify affected patients
according to their biochemical profile. ROC cutoffs were
calculated by the Youden’s index through the identification of
the best pair of sensitivity and specificity.
Statistical analyses were performed using the Statistical
Package for the Social Sciences’ (SPSS) software for Windows
(version 16.0; SPSS Inc, Chicago, IL, USA) and Sigma Plot (version
11.00; Systat Software Inc, San Jose, CA, USA). For all
comparisons, p< 0.05 was considered statistically significant.
Results
Trial 1
Clinical and demographic characteristics of both PHPT patients
and controls together with the diagnostic procedure(s) used
for the localization of enlarged parathyroid glands in PHPT
patients are summarized in Table 1.
Serum Ca was significantly higher in PHPT patients than
in controls (p< 0.0001) (Table 2). Conversely, serum P was
significantly lower in PHPT patients than in controls (p< 0.0001)
(Table 2). Serum albumin obtained from the record charts
allowed the calculation of corrected Ca in 73 PHPT patients
(75.25%) and 67 controls (69.8%). Serum corrected Ca
was significantly higher in PHPT patients than in controls
(p< 0.0001) (Table 2). Both serum Ca/P and corrected Ca/P were
significantly higher in patients with PHPT than in controls
(p< 0.0001) (Table 2). As expected, serum PTH was higher in
patients with PHPT than in controls (p< 0.0001). Age and serum
creatinine did not differ between the two groups (Table 2).
The diagnostic value of diagnostic parameters included in
the protocol and their ability to diagnose PHPT are summa-
rized in Table 3. The Ca/P was able to correctly identify 84 of
the 97 PHPT patients when a threshold of 2.71 (3.5 if Ca and P
are measured in mg/dL) was used, while only 12 of the
96 controls were erroneously diagnosed as having PHPT
(Figs. 1 and 2). The Ca/P threshold of 2.71, obtained by ROC
Fig. 1. STARD flow diagram of participants through the study summarizing patients’ recruitment and diagnostic accuracy of Ca/P for Trial 1. 3.5 if Ca
and P aremeasured inmg/dL (conventional units). Ca/P¼ serum calcium to phosphorous ratio; PHPT: primary hyperparathyroidism; STARD¼ STAndards
for the Reporting of Diagnostic accuracy studies.
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curve analysis, performed at best for the highest sensitivity
and specificity (Fig. 3). With this cutoff, the diagnostic power of
Ca/P in identifying patients with PHPT was better than that of
either serum Ca or corrected Ca and of all other diagnostic
procedures, with exception of serum PTH, as expected
(Table 3). Accordingly, sensitivity, NPV, and accuracy of Ca/P
were greater than that of serum Ca and corrected Ca and other
diagnostic procedures (Table 3). The best specificity was
obtained by serum Ca and corrected Ca and PTH, as expected
(Table 3). Concerning serum PTH, a normal serum PTH was a
prerequisite for the enrolment of controls, thus overestimating
its diagnostic value in this setting.
The combined use of Ca/P and serum Ca (which was
considered positive when at least one of the two biochemical
parameters was above the cutoff) had the best sensitivity with a
concomitant, very high specificity together with PPV, NPV, and
accuracy higher than Ca/P alone (Table 3).
The results obtained by considering only the subgroup of
patients with NCPHPT were similar to those obtained consider-
ing all the subjects, with the exception of a lower diagnostic
performance of both serum Ca and corrected Ca, as expected
(Table 4). AmongNCPHPT, the Ca/Pwas able to identify 25 out of
the 35 patients that could not be identified by serum Ca alone or
by corrected Ca alone.
Table 1. Demographic and Clinical Characteristics of All Study Participants
Subjects n (%)
Controls (n¼ 96)
Sex
Females 44 (45.36)
Males 52 (54.63)
PHPT (n¼ 97)
Sex
Females 69 (71.13)
Males 28 (28.87)
PHPT pattern
Hypercalcemic 62 (63.9)
NCPHPT 35 (36.1)
Morphological evidence of enlarged parathyroid
Not localized enlarged parathyroid 2 (2.1)
Localized enlarged parathyroid 95 (97.9)
Localization according to each diagnostic procedure
US (n¼ 97a) 89 (91.7)
CT (n¼ 12a) 9 (9.2)
FNAB
Cytological evidence (n¼ 50a) 11 (11.3)
PTH in washing fluid of fine needle aspiration biopsy (n¼ 48a) 36 (37.1)
Scintigraphy (n¼ 57a) 35 (36.1)
Localization in patients who underwent surgery 56 (57.8)b
Histological evidence at parathyroidectomy 54 (55.7)
No evidence of enlarged parathyroidectomy 2 (2.1)
Localization according to combined diagnostic procedures (radiological and cytological) in not-operated patients 41 (42.3)
By all 4 diagnostic procedures (USþFNABþScintigraphyþCT) 1 (1)c
By 3 of the 4 diagnostic procedures 4 (4.1)c
USþFNABþScintigraphy 3 (3.1)c
USþFNABþCT 1 (1)c
By 2 of the 4 diagnostic procedures 22 (22.7)c
USþFNAB 8 (8.3)c
USþScintigraphy 12 (12.4)c
USþCT 2 (2.1)c
By 1 of the 4 diagnostic procedures 14 (14.4)c
US 13 (13.4)c
Scintigraphy 1 (1)c
Diagnostic tools used to clinical confirm the diagnosis of PHPT are summarized. Of the 41 not-operated patients, 14 did not have clinical indications for
surgery, 8 were not operated because of high risk related to surgical procedures, 8 patients refused to undergo surgery, and 11 patients were still waiting
for surgery at the time of data collection.
PHPT¼primary hyperparathyroidism; NCPHPT¼normocalcemic PHPT; US¼ ultrasound; CT¼ computed tomography; FNAB¼ fine needle aspiration;
PTH¼parathyroid hormone.
aNumber of patients who underwent the diagnostic procedure.
bIn our series, 56 of the 97 patients with PHPT underwent surgery, while the remaining 41 were not operated. All 56 patients who underwent surgery
had clinical indications to surgery, according to criteria established by guidelines on PHPT.(8)
cPercentage refers only to operated patients (n¼ 41).
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Trial 2
The starting database enclosed 968,941,944 records, of which
42,535 datasets had complete data required (PTH, Ca, P, and
creatinine) as inclusion/exclusion criteria (Fig. 4). A total of
19,898 records were excluded because of a GFR<30mL/min and
113 for age below 18 years or above 90 years. A total of 22,524
datasets remained and were used to evaluate data distribution.
Ca and P were normally distributed with 95% CI from 2.1 to
2.5mmol/L for Ca and from 0.8 to 1.4mmol/L for P. PTH showed
a leptokurtic distribution (asymmetry 2.11þ0.02), thus a
logarithmic transformation was applied to obtain a normal
distribution with a 95% CI between 17.5 and 78.0 ng/L. A total of
2077 records showed PTH or Ca or both under the 5th centile of
distribution, possibly representing samples from patients with
hypoparathyroidism. The latter were excluded and the final
analysis was performed on 20,447 datasets (Fig. 4). Among
these, 590 datasets (2.9%) were above the 95th centile for both
PTH and Ca, possibly representing the group of PHPT records
(Fig. 4).
The Ca/P was able to correctly identify 441 of the 590 (74.7%)
PHPT records when a threshold of 2.71 (3.5 if Ca and P are
measured in mg/dL) was used, while only 1762 of the 19857
(8.8%) controls records were erroneously diagnosed as having
PHPT (Fig. 4).
The Ca/P ratio was significantly higher in PHPT records (3.18;
95% CI, 1.48 to 7.55) compared to controls records (2.13; 95% CI,
1.03 to 8.58) (p< 0.001).
By ROC curve analysis a threshold of 2.64 (3.4 if Ca and P are
measured in mg/dL) for the Ca/P ratio was indicated by the best
pair of values for the sensitivity and specificity (Fig. 5). With this
cutoff, the diagnostic power of Ca/P ratio showed a sensitivity of
80% and a specificity of 88% (Fig. 5).
Discussion
This study demonstrates, for the first time, that the diagnostic
power of the serum Ca/P ratio is of superior value, compared to
serum Ca (or corrected Ca) alone, for the diagnosis of PHPT,
especially in the subgroup of NCPHPT patients. In fact, a Ca/P
value above 2.71 (3.5 if Ca and P are measured in mg/dL)
resulted to be an accurate, highly sensitive, and highly specific
tool for the diagnosis of PHPT. More importantly, both sensitivity
Table 3. Diagnostic Value of Several Parameters for the Diagnosis of PHPT in the Entire Cohort
Cutoff Sensitivity Specificity PPV NPV Accuracy
Ca/P 2.71 (3.5 CU) 86 87 87 86 87
Corrected Ca/P ratio 2.71 (3.5 CU) 89 91 91 88 90
Serum PTH 88 86 100 100 87 93
Serum Ca 2.65 (10.6 CU) 64 100 100 73 82
Serum corrected Ca 2.65 (10.6 CU) 63 99 98 71 80
Serum P 2.5 53 93 88 66 72
Combined Ca/P and/or serum Caa 2.71/2.65 (3.5/10.6 CU) 90 87 88 89 93
Values are expressed as percentages.
PHPT¼primary hyperparathyroidism; Ca¼ calcium; P¼phosphorous; Ca/P¼ serum calcium to phosphorous ratio; CU¼ conventional units (Ca and P
measured in mg/dL); Sensitivity¼number of true positives divided by the number of true positives plus the number of false negatives;
Specificity¼number of true negatives divided by the number of true negatives plus the number of false positives; PPV¼positive predictive value:
number of true positives divided by the number of true positives plus the number of false positives; NPV¼negative predictive value: number of true
negatives divided by the number of true negatives plus the number of false negatives; Accuracy¼number of true positives plus the number of
true negatives divided by the number of true positives plus the number of true negatives plus the number of false positives plus the number of false
negatives.
aCombined Ca/P and/or serum Ca was considered positive when at least one of the two biochemical parameters was above the cutoff.
Table 2. Age, Biochemical, and Hormonal Differences Between Patients With PHPT and Controls
Normal range PHPT (n¼ 97) Controls (n¼ 96) p
Age (years) 18–90a 63 (23–90) 58.5 (20–89) 0.34
Serum Ca (mmol/L) 2.12–2.65 2.75 (2.35–3.87) 2.35 (2.07–2.55) <0.0001
Serum P (mmol/L) 0.81–1.65 0.77 (0.45–1.26) 1.14 (0.68–1.45) <0.0001
Ca/P – 3.56 (2.03–6.81) 2.09 (1.55–3.56) <0.0001
Serum PTH (ng/L) 15–88 135.2 (57.6–1748) 32.1 (14–80.7) <0.0001
Serum 25-OH vitamin D (nmol/L) 74.9–249.6 40.7 (10–110) 50.8 (10–103) 0.008
Serum creatinine (mmol/L) 44.2–123.8 70.7 (44.2–132.6) 70.7 (44.2–150.2) 0.454
Serum albumin (g/L)b 35–50 43 (27–48) 41 (26–50) 0.01
Serum corrected Ca (mmol/L)b – 2.75 (2.32–3.97) 2.3 (2.1–2.67) <0.0001
Corrected Ca/P ratiob – 3.56 (2.09–6.81) 2.01 (1.63–3.41) <0.0001
Measurements are expressed as median (minimum–maximum).
PHPT¼primary hyperparathyroidism; Ca¼ serum calcium; P¼ serum phosphorous; Ca/P¼ serum calcium to phosphorous ratio.
aAge range for enrolment in this study.
bAvailable in 73 PHPT patients (75.25%) and 67 controls (69.8%).
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and accuracy further increases if serum Ca and Ca/P are used
in combination (Table 3). These results were obtained from
a retrospective clinical trial and were confirmed by a
second, independent analysis, performed using a very large
database extracted from the entirety of laboratory diagnostic
determinations of a large routine laboratory, consisting of
over 900 million data records. Therefore, using two different
experimental approaches, we conclude that the serum Ca/P
ratio should be considered a simple and very powerful
diagnostic tool of PHPT.
That the Ca/P has a good diagnostic value in detecting PHPT is
not surprising in view of (i) the inverse relationship between
serum Ca and P in physiological conditions (ie, healthy, control
subjects)(24,25); (ii) the almost constantly divergent pattern of
serum Ca (increasing) and P (decreasing) in PHPT(1,3,13,24); (iii) the
unchanged or increased serum P in case of hypercalcemia not
due to PHPT(27); and (iv) the rarity of hypophosphatemia not due
to PHPT.(4,28) In the case of malignant hypercalcemia due to
PTH-like peptides, Ca/P is expected not to distinguish it from
PHPT, because serum P tends to be low, but themeasurement of
PTH can help differentiating the two forms.(27)
This study proves that Ca/P is a highly reliable tool, especially
in NCPHPT patients, who are not clearly identified as having
PHPT by the measurement of serum Ca (or corrected Ca)
alone.(7,29) In these patients Ca/P had the best diagnostic value in
terms of sensitivity and accuracy compared to other diagnostic
tools such as serum Ca and corrected Ca. Accordingly, both
serum Ca and ionized Ca alone fails to recognize some cases of
PHPT with normal (or fluctuating around the upper normal limit)
serum Ca,(29,30) the diagnosis of NCPHPT requiring the
demonstration of elevated serum PTH.(7) Serum P alone was
unreliable in the diagnosis of PHPT, in accordance with all
previous studies that evaluated this parameter alone and never
in combination with Ca.(11,12,15,18) Thus, Ca/P is more accurate
than either serum P or Ca alone, avoiding false-negative
diagnoses, as suggested by the 25 of 35 (71%) patients
recognized as having NCPHPT in this study. The timely diagnosis
of PHPT is useful for preventing the development of comorbid-
ities related to PHPT,(31–33) as well as the evolution toward
symptomatic, overt PHPT,(34) the latter occurring in a relevant
percentage (about 40%) of cases.(8)
In clinical practice, the use of Ca/P has the potential of
becoming a useful tool for the diagnosis of PHPT and might
Fig. 2. Distribution of Ca/P values between controls and PHPT patients
according to the Ca/P threshold of 2.71 (3.5 in conventional units with Ca
and P measured in mg/dL). Ca/P¼ serum calcium to phosphorous ratio;
SI¼ International System of Units (Ca and P measured in mmol/L);
CU¼ conventional units (Ca and P measured in mg/dL); PHPT¼primary
hyperparathyroidism.
Fig. 3. ROC curve analysis for Ca/P together with cutoff, sensitivity, specificity, area under the curve, standard error, and 95% confidence interval values
for Trial 1. CU¼ conventional units (Ca and P measured in mg/dL); AUC¼ area under the curve.
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become an inexpensive, first-line examination in the workup of
PHPT, with serum PTH as a successive measurement, useful to
confirm the diagnosis of PHPT when Ca/P is above 2.71 (3.5 if Ca
and P are measured in mg/dL). It is well known that serum P
alone is unreliable for diagnosing PHPT, and it is currently
measured neither in clinical(18) nor in research settings, with the
exception of few studies,(35) in accordance to clinical guidelines
recommendations.(8,36–38) Here we suggest that serum P should
be measured together with Ca allowing calculating Ca/P to be
inexpensive,(39) and not requiring further technical equipment/
skills beyond those already available for serumCameasurement.
In addition, Ca/P could be considered a good candidate for PHPT
screening, especially if integrated with the serum Ca value.
This study consists of a retrospective clinical trial and a
retrospective data mining and statistical analysis of a large set
of data from a high-throughput routine laboratory. The results
of both trials are concordant in identifying the serum Ca/P as
a powerful diagnostic tool for PHPT. Both approaches have
strengths and limitations. The main strengths are (i) the
simple and straightforward design of the retrospective clinical
trial in which all patients with PHPT had the biochemical
diagnosis confirmed by documented enlarged parathyroid/s at
Table 4. Diagnostic Value of Several Parameters for the Diagnosis of PHPT in the NHPHPT Cohort
Cutoff Sensitivity Specificity PPV NPV Accuracy
Ca/P 2.71 (3.5 CU) 71 88 68 89 83
Corrected Ca/P ratio 2.71 (3.5 CU) 67 91 73 88 85
Serum PTH 88 89 100 100 96 97
Serum Ca 2.65 (10.6 CU) 0 100 0 73 73
Serum corrected Ca 2.65 (10.6 CU) 13 99 75 76 76
Serum P 2.5 26 93 56 77 75
Values are expressed as percentages.
PHPT¼primary hyperparathyroidism; NCPHPT¼normocalcemic hyperparathyroidism; Ca¼ calcium; P¼phosphorous; Ca/P¼ serum calcium to
phosphorous ratio; CU¼ conventional units (Ca and Pmeasured inmg/dL); Sensitivity¼number of true positives divided by the number of true positives
plus the number of false negatives; Specificity¼number of true negatives divided by the number of true negatives plus the number of false positives;
PPV¼positive predictive value: number of true positives divided by the number of true positives plus the number of false positives; NPV¼negative
predictive value: number of true negatives divided by the number of true negatives plus the number of false negatives; Accuracy¼number of true
positives plus the number of true negatives divided by the number of true positives plus the number of true negatives plus the number of false positives
plus the number of false negatives.
Fig. 4. STARD flow diagram of participants through the study summarizing patients’ recruitment and diagnostic accuracy of Ca/P for Trial 2. 3.5 if Ca
and P are measured in mg/dL (conventional units). GFR¼glomerular filtration rate; PTH¼parathyroid hormone; Ca¼ serum calcium; Ca/P¼ serum
calcium to phosphorous ratio; PHPT¼primary hyperparathyroidism; STARD¼ STAndards for the Reporting of Diagnostic accuracy studies.
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histological verification (55.7%) or by imaging (Table 1); and
(ii) the very large data set and rigorous statistical approach to
the information deriving from it in the second trial. The
retrospective nature represents the main limit of this study,
but assures a correct assignment to control or PHPT groups in
the clinical study (Trial 1). The results refer to a single center
and large, long-term, prospective, multicenter studies on
larger sample size are required to confirm and validate our
findings. Other limits of this study are that patients and
controls were not very well matched on gender in Trial 1, and
the big data approach does not allow having a certain
diagnosis for each patient because that patient’s record charts
are unavailable because blood samples come from several
hospitals (5) and several points where blood samples are
obtained from outpatients. Furthermore, the lack of a group of
patients with FHH limits the use of serum Ca/P in the
differential diagnosis between PHPT and FHH and we do not
know its diagnostic value in this setting.
In conclusion, this study shows, for the first time and using
two independent approaches, that the serum Ca/P ratio is a
valuable, highly sensitive, highly specific tool for the diagnosis of
PHPT and has the potential of becoming a good, cost-effective,
first-line examination in the clinical workup of PHPT diagnosis
and screening, especially in combination with serum Ca. This
might be particularly useful especially in laboratory/medical
settings relying on limited resources, in which PTH determina-
tion is difficult or not possible. In this regard the use of the Ca/P
ratio for the diagnosis of PHPT can be extended to every clinical
and laboratory setting worldwide, including developing coun-
tries, reducing health inequalities(40) due to limited access to
diagnostic facilities, such as hormone measurements.(41,42)
Thanks to its simplicity, the Ca/P ratio could be useful in clinical
settings characterized by large inflow of patients (eg, general
practitioner, emergency room, PHPT screening of osteoporotic
patients). In all these conditions Ca/P may perform very well,
allowing cost savings and selecting patients as candidates for
second-line diagnostic procedures such as PTH assay and
imaging.
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